FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average I	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hofmeister Robert</u>				2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [TCRR]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				/ner		
	(F R2 THERA NEY STRE	PEUTICS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/12/2020								X Officer (give title Other (specify below) Chief Scientific Officer					
(Street) CAMBRIDGE MA 02142			4.	If Amendment, Date of Original Filed (Month/Day/Year)										1				
(City)	(S	tate)	(Zip)															
		Tal	ole I - Noi	n-Deri	vativ	re Se	ecuri	ties A	cquired	Dis	posed o	f, or Be	neficial	ly Owned				
		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		r, Transaction Disposed Code (Instr. 5)		ties Acquired (A) or d Of (D) (Instr. 3, 4 an		Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
						Code	v	Amount	(A) or (D)	Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
Common Stock			11/1	1/12/2020				M ⁽¹⁾		9,998	,998 A		4 48,	48,848		D		
Common Stock			11/1	/12/2020				S ⁽¹⁾		9,998	D	\$25.	1 38,	38,850		D		
Common Stock 11			11/1	2/202	/2020			M ⁽¹⁾		10,002 A		\$0.7	4 48,	48,852		D		
Common Stock 11/1			2/202	2/2020		S ⁽¹⁾		10,002 D \$		\$25.	1 38,	38,850		D				
			Table II -											Owned				
Derivative Conversion Date Exercise (Month/Day/Year) if all		3A. Deemed Execution I if any (Month/Day	d 4. Date, Transaction Code (Instr		action	5. Number n of		6. Date Exercisable Expiration Date (Month/Day/Year)		able and	nvertible securitie 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.74	11/12/2020			M ⁽¹⁾			9,998	12/07/203	8(2)	12/07/2027	Common Stock	9,998	\$0.00	12,34	8	D	
Stock Option (Right to Buy)	\$0.74	11/12/2020			M ⁽¹⁾			10,002	12/13/20:	7 ⁽³⁾	12/13/2026	Common Stock	10,002	\$0.00	25,730	0	D	

Explanation of Responses:

- 1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. 25% of this option vested and become exercisable on December 7, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
- 3. 25% of this option vested and become exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

Margaret Siegel as Attorney-in-**Fact**

** Signature of Reporting Person

11/13/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.